Clinical application of 99mTc‐labeled peptides for tumor imaging: Current status and future directions
Authors:
Open Access
- 21 January 2024
- journal article
- review article
- Published by Wiley in iRADIOLOGY
- Vol. 2 (1) , 17-34
Abstract
Targeting receptors overexpressed on cancer cells with radiolabeled peptides has become a crucial aspect of molecular imaging in oncology. Small peptides offer favorable characteristics for tumor targeting with minimal side effects and toxicity owing to their small size and simple radiolabeling protocols. Among them, somatostatin analogs have received regulatory approval for the diagnosis and treatment of neuroendocrine tumors. Cyclic RGD (Arg‐Gly‐Asp) peptides, bombesin analogs, and glucagon‐like peptide‐1 analogs are currently under development and/or undergoing clinical trials. The most used radionuclides for tumor imaging include 99mTc and 111In for single‐photon emission computed tomography, 68Ga and 18F for positron emission tomography. This review highlights the clinical potential and future prospects of 99mTc‐labeled peptides for tumor imaging.Keywords
This publication has 65 references indexed in Scilit:
- 99mTc-Galacto-RGD2: A Novel 99mTc-Labeled Cyclic RGD Peptide Dimer Useful for Tumor ImagingMolecular Pharmaceutics, 2013
- Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of CancerTheranostics, 2012
- Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic StabilityTheranostics, 2011
- Molecular imaging: current status and emerging strategiesClinical Radiology, 2010
- Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via BivalencyBioconjugate Chemistry, 2009
- 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and PharmacokineticsBioconjugate Chemistry, 2009
- Improving Tumor-Targeting Capability and Pharmacokinetics of 99mTc-Labeled Cyclic RGD Dimers with PEG4 LinkersMolecular Pharmaceutics, 2008
- Isolation, Characterization, and Biological Evaluation ofSynandAntiDiastereomers of [99mTc]Technetium Depreotide: a Somatostatin Receptor Binding Tumor Imaging AgentJournal of Medicinal Chemistry, 2007
- Impact of PKM Linkers on Biodistribution Characteristics of the 99mTc-Labeled Cyclic RGDfK DimerBioconjugate Chemistry, 2006
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003